Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at email@example.com. On November 9, 2016, Ligand announced that it would not be able to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and that it was reviewing a potential restatement. On November 14, 2016, the Company announced that it would restate financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error. Ligand also disclosed that its management determined that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.